Biogen Inc. (NASDAQ: BIIB) announced positive results from the phase 2 portion of its AMETHYST study evaluating litifilimab for cutaneous ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE